The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.
Inclusion criteria:
Exclusion criteria:
clinicaltrials@novonordisk.com
Sponsor staff involved in the clinical trial is masked according to company standard procedures.
Participants will receive cagrilintide along with placebo matched to semaglutide in device 1 and placebo matched to cagrilintide in device 2 subcutaneously (s.c) once weekly for 26 weeks.
Participants will receive cagrilintide in device 2 and placebo matched to cagrilintide along with placebo matched to semaglutide in device 1 s.c once weekly for 26 weeks.
Participants will receive placebo matched to cagrilintide in device 2 and placebo matched to cagrilintide along with placebo matched to semaglutide in device 1 s.c once weekly for 26 weeks.
Athens, 115 28, Greece
Peristeri, 121 31, Greece
Thessaloniki, 546 42, Greece
Caldas da Rainha, 2500-176, Portugal
Figueira da Foz Municipality, 3094-001, Portugal
A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity
A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity